Analysts Set Expectations for RARE Q2 Earnings

Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE - Free Report) - Equities researchers at William Blair issued their Q2 2025 earnings per share estimates for Ultragenyx Pharmaceutical in a research note issued to investors on Thursday, July 10th. William Blair analyst S. Corwin anticipates that the biopharmaceutical company will post earnings per share of ($1.31) for the quarter. William Blair currently has a "Outperform" rating and a $65.00 target price on the stock. The consensus estimate for Ultragenyx Pharmaceutical's current full-year earnings is ($5.18) per share. William Blair also issued estimates for Ultragenyx Pharmaceutical's Q3 2025 earnings at ($1.32) EPS, Q4 2025 earnings at $0.71 EPS, Q1 2026 earnings at ($1.27) EPS, Q2 2026 earnings at ($0.91) EPS, Q3 2026 earnings at ($0.86) EPS, Q4 2026 earnings at $1.09 EPS and FY2026 earnings at ($1.95) EPS.

A number of other brokerages also recently issued reports on RARE. Wedbush cut their price target on Ultragenyx Pharmaceutical from $35.00 to $34.00 and set a "neutral" rating on the stock in a report on Monday. JPMorgan Chase & Co. increased their price target on shares of Ultragenyx Pharmaceutical from $104.00 to $117.00 and gave the company an "overweight" rating in a research report on Thursday, March 27th. Guggenheim reaffirmed a "buy" rating and issued a $64.00 price target on shares of Ultragenyx Pharmaceutical in a report on Friday, June 20th. Piper Sandler cut their price target on shares of Ultragenyx Pharmaceutical from $140.00 to $115.00 and set an "overweight" rating on the stock in a report on Monday, March 17th. Finally, Morgan Stanley lowered their price target on Ultragenyx Pharmaceutical from $65.00 to $55.00 and set an "overweight" rating for the company in a report on Monday. One investment analyst has rated the stock with a hold rating and thirteen have issued a buy rating to the company. According to data from MarketBeat.com, Ultragenyx Pharmaceutical currently has an average rating of "Moderate Buy" and a consensus target price of $83.64.

Ultragenyx Pharmaceutical Trading Down 3.7%

Shares of RARE traded down $1.09 during mid-day trading on Monday, hitting $28.15. The company's stock had a trading volume of 398,982 shares, compared to its average volume of 929,702. Ultragenyx Pharmaceutical has a 52-week low of $28.04 and a 52-week high of $60.37. The company's 50-day moving average is $36.47 and its 200-day moving average is $38.71. The firm has a market capitalization of $2.66 billion, a price-to-earnings ratio of -4.80 and a beta of 0.26.

Ultragenyx Pharmaceutical (NASDAQ:RARE - Get Free Report) last announced its quarterly earnings results on Tuesday, May 6th. The biopharmaceutical company reported ($1.57) earnings per share for the quarter, missing the consensus estimate of ($1.54) by ($0.03). Ultragenyx Pharmaceutical had a negative return on equity of 186.49% and a negative net margin of 93.04%. The business had revenue of $139.29 million during the quarter, compared to analysts' expectations of $145.98 million. During the same period in the previous year, the company posted ($2.03) EPS. Ultragenyx Pharmaceutical's revenue for the quarter was up 28.0% on a year-over-year basis.

Insider Activity

In other Ultragenyx Pharmaceutical news, Director Corazon (Corsee) D. Sanders sold 2,405 shares of the company's stock in a transaction that occurred on Friday, June 20th. The stock was sold at an average price of $37.39, for a total value of $89,922.95. Following the sale, the director owned 15,344 shares in the company, valued at approximately $573,712.16. This represents a 13.55% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this link. Over the last ninety days, insiders sold 3,167 shares of company stock valued at $118,824. Insiders own 5.50% of the company's stock.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the company. GAMMA Investing LLC boosted its position in Ultragenyx Pharmaceutical by 76.2% during the first quarter. GAMMA Investing LLC now owns 747 shares of the biopharmaceutical company's stock worth $27,000 after purchasing an additional 323 shares in the last quarter. Parallel Advisors LLC increased its holdings in Ultragenyx Pharmaceutical by 1,061.9% in the 2nd quarter. Parallel Advisors LLC now owns 732 shares of the biopharmaceutical company's stock worth $27,000 after acquiring an additional 669 shares in the last quarter. Aster Capital Management DIFC Ltd purchased a new stake in Ultragenyx Pharmaceutical in the 4th quarter worth $35,000. ANTIPODES PARTNERS Ltd purchased a new stake in Ultragenyx Pharmaceutical in the 1st quarter worth $57,000. Finally, Headlands Technologies LLC purchased a new position in Ultragenyx Pharmaceutical in the 1st quarter valued at about $59,000. Hedge funds and other institutional investors own 97.67% of the company's stock.

Ultragenyx Pharmaceutical Company Profile

Ultragenyx Pharmaceutical Inc, a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Latin America, Japan, Europe, and internationally. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast growth factor 23 for the treatment of X-linked hypophosphatemia, as well as tumor-induced osteomalacia; Mepsevii, an enzyme replacement therapy for the treatment of children and adults with Mucopolysaccharidosis VII; Dojolvi for treating long-chain fatty acid oxidation disorders; and Evkeeza (evinacumab) for the treatment of homozygous familial hypercholesterolemia.